{"canonical":"https://abierto.us/vendors/inhalon-biopharma-inc-hfqsj2gmnru6","key":"HFQSJ2GMNRU6","name":"INHALON BIOPHARMA, INC.","uei":"HFQSJ2GMNRU6","city":"MORRISVILLE","state":"NC","awards":2,"obligated":"5410293.00","notices_won":0,"top_agency_name":"Defense Health Agency","top_naics":"541715","cage":"87U21","parent_name":"INHALON BIOPHARMA, INC.","also_known_as":[],"country":"USA","actions":4,"first_action":"2024-09-16","last_action":"2025-09-22","breakdowns":{"naics":[{"key":"541715","name":null,"awards":2,"obligated":"5410293.00"}],"places":[{"key":"NC","name":null,"awards":2,"obligated":"5410293.00"}],"agencies":[{"key":"97DH","name":"Defense Health Agency","awards":2,"obligated":"5410293.00"}],"award_types":[{"key":"DEFINITIVE CONTRACT","name":null,"awards":2,"obligated":"5410293.00"}],"competition":[{"key":"FULL AND OPEN COMPETITION","name":null,"awards":2,"obligated":"5410293.00"}],"product_service_codes":[{"key":"AN13","name":null,"awards":1,"obligated":"3175643.00"},{"key":"AN12","name":null,"awards":1,"obligated":"2234650.00"}]},"awards_list":[{"award_key":"CONT_AWD_HT942525CE039_9700_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_HT942525CE039_9700_-NONE-_-NONE-/","piid":"HT942525CE039","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"HFQSJ2GMNRU6","recipient_name":"INHALON BIOPHARMA, INC.","recipient_uei":"HFQSJ2GMNRU6","recipient_cage":"87U21","recipient_city":"MORRISVILLE","recipient_state":"NC","sub_name":"Defense Health Agency","office_name":"ARMY MED RES ACQ ACTIVITY","office_key":"o-HT9425","first_action_date":"2025-09-22","last_action_date":"2025-09-22","actions":1,"obligated":"3175643.00","current_total_value":"3175643.00","potential_total_value":"3175643.00","naics":"541715","psc":"AN13","extent_competed":"FULL AND OPEN COMPETITION","set_aside":"NO SET ASIDE USED.","offers_received":44,"description":"A PHASE 1 PLACEBO-CONTROLLED DOSE-ESCALATION SAFETY AND PHARMACOKINETIC STUDY OF IN-007, A NEBULIZED, PAN-SARS ACE2-DECOY THERAPEUTIC FOR PANDEMIC PREPAREDNESS","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null},{"award_key":"CONT_AWD_HT942524C0076_9700_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_HT942524C0076_9700_-NONE-_-NONE-/","piid":"HT942524C0076","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"HFQSJ2GMNRU6","recipient_name":"INHALON BIOPHARMA, INC.","recipient_uei":"HFQSJ2GMNRU6","recipient_cage":"87U21","recipient_city":"MORRISVILLE","recipient_state":"NC","sub_name":"Defense Health Agency","office_name":"ARMY MED RES ACQ ACTIVITY","office_key":"o-HT9425","first_action_date":"2024-09-16","last_action_date":"2025-09-04","actions":3,"obligated":"2234650.00","current_total_value":"2234650.00","potential_total_value":"2234650.00","naics":"541715","psc":"AN12","extent_competed":"FULL AND OPEN COMPETITION","set_aside":"NO SET ASIDE USED.","offers_received":47,"description":"DEVELOPING IN-007 AS A WIDELY DEPLOYABLE INHALED TREATMENT AGAINST PATHOGENS UTILIZING HUMAN ACE2 FOR VIRAL ATTACHMENT AND ENTRY","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null}],"awards_total":2,"awards_page":1,"won":[],"won_total":0,"solicitations_won":[]}